26 C
Vientiane
Monday, May 5, 2025
spot_img
Home Blog Page 413

SOL ARENA USHERS IN A NEW ERA OF CASUAL GAMING AND CRYPTO WAGERING ON SOLANA, WITH $CHILL TOKEN LAUNCHING SOON

  • SOL Arena, the Web3 multiplayer battle game developed by Chillchat, will launch its $CHILL token at end-March 2025, following its sold-out Challengers NFT mint on Magic Eden on February 6, 2025.
  • Delivering a fresh take on snake-like gameplay on the Solana blockchain, SOL Arena has attracted 80,000+ global players since its Open Beta launch in September 2024.
  • Backed by Solana Ventures, Crypto.com Capital, and Big Brain Holdings, Chillchat aims to pioneer innovation in Web3 gaming by marrying casual gameplay with high-stakes crypto wagering in massive real-time battles.

BANGKOK, March 6, 2025 /PRNewswire/ — SOL Arena, a high-stake multiplayer battle game powered by Solana and now live in Open Beta, will launch its $CHILL token at end-March 2025, which will allow players to wager $CHILL in real-time crypto battles, or stake for in-game and ecosystem rewards. After welcoming more than 80,000 players worldwide since its Open Beta began on September 20, 2024, SOL Arena’s highly anticipated $CHILL token launch follows a sold-out Challengers NFT mint on Magic Eden last month.

SOL Arena, the Web3 multiplayer battle game developed by Chillchat Games, will launch its $CHILL token at end-March 2025.
SOL Arena, the Web3 multiplayer battle game developed by Chillchat Games, will launch its $CHILL token at end-March 2025.

Developed by Chillchat, a Bangkok-based Web3 gaming studio, SOL Arena unites casual snake-style gameplay with massive real-time battles and large-scale crypto wagering. By pairing the simplicity of casual gaming with the thrill of real crypto stakes, SOL Arena delivers a fresh take on Web3 gaming on Solana — appealing to both casual gamers and competitive enthusiasts.

To support its continued growth and development, Chillchat previously secured US$8.69M in seed funding, led by Solana Ventures, Crypto.com Capital, and Big Brain Holdings. Matt Beck, Head of Investments at Solana Ventures said: “SOL Arena is introducing a new way to engage with crypto gaming — where every match matters because there’s something real at stake. This is exactly the kind of innovation that will drive Web3 gaming forward.”

SOL Big Brain of Big Brain Holdings said: “I’m hyped to see how SOL Arena evolves over time. Its approach to merging casual gaming with real-time wagering is already making waves in the Solana community.”

A New Era of Web3 Gaming: Real-Time Crypto Wagering at Scale
SOL Arena merges the simplicity of popular multiplayer snake games with intense extraction gameplay, allowing up to 50 players to compete in real-time battles to collect noCHILL, outmaneuver opponents, and strategically withdraw their winnings. The upcoming High Roller Mode will introduce crypto wagering with $CHILL, raising the stakes for both casual players and high-level competitors. SOL Arena integrates the dynamic, community-driven Solana ecosystem directly into the game, where memecoin projects, NFT communities, and token holders unite under shared teams.

“Our vision is to merge casual gaming with degenerate memecoin activity and crypto network effects,” said James Au, CEO and Game Director of Chillchat, “to deliver an exciting new player experience that redefines the thrill of ‘winning’.”

What’s Next? Token Launch and Mobile Play
Following the Challengers NFT mint in February 2025, SOL Arena’s next significant milestone is the launch of its ecosystem token, $CHILL, at the end of March.

The $CHILL token fuels SOL Arena’s in-game economy, allowing players to wager it in High Roller mode, or stake it to earn in-game rewards. Players can qualify for a $CHILL airdrop by playing the game and extracting noCHILL, or by holding Chillchat Origin or SOL Arena Challengers’ NFTs.

The official launch of the SOL Arena game, which will introduce new features such as Seasons, will include mobile versions for both iOS and Android available in mid-2025.

Join the SOL Arena Battles Now
SOL Arena is free to play now at solarena.io. Jump in, collect and extract noCHILL, and start climbing the leaderboards to secure your spot in the upcoming $CHILL airdrop.

For more on SOL Arena:
Website
Discord
X (Twitter)
Telegram

About Chillchat
Chillchat is a Bangkok-based Web3 gaming studio dedicated to creating fun, accessible, and innovative blockchain-powered experiences. SOL Arena is the studio’s flagship title, merging traditional gaming fundamentals with real crypto stakes, all secured by Solana’s lightning-fast network. With an aim to pioneer the next generation of Web3 gaming, Chillchat invests in bold ideas that blend community engagement, financial incentives, and immersive gameplay.

WESTIN WELLNESS WEEKEND : WELLNESS BEFORE THE RUN

Prepare, recover, and recharge with expert-led wellness experiences tailored for runners

SINGAPORE, March 6, 2025 /PRNewswire/ — The second Westin Wellness Weekend, from 25 to 27 April 2025, is dedicated to preparing both mind and body for the ultimate running experience—whether it’s a 5KM, 10KM, half marathon, or marathon. This invigorating 3D2N retreat at The Westin Singapore offers a holistic approach to pre-run readiness, featuring expert-led sessions on mental resilience, revitalizing yoga, mobility for better movement, and a mindful silent breakfast, all designed to optimize performance and well-being.

Westin Wellness Weekend at The Westin Singapore
Westin Wellness Weekend at The Westin Singapore

From the moment you arrive, immerse yourself in a sensory welcome with our signature White Tea scent, setting the stage for a truly relaxing stay. Check into one of our spacious guest rooms, thoughtfully designed with premium amenities, including the Sleep Well Lavender Balm and our iconic next generation Heavenly® Bed, ensuring a restful night’s sleep.

Spend the afternoon leisurely exploring the hotel’s comprehensive facilities before making your way to the exclusive Presidential Suite for an engaging welcome dinner where you can meet your wellness hosts for the weekend. This special evening also highlights Curated Culture, a pioneering homegrown brand revolutionizing the health and wellness beverage industry with innovative, science-backed formulations. Next, learn about managing urban stressors with registered psychologist, Felix Lim, PhD, followed by a short relaxing sound bath to let your mind unwind for better sleep.

Rise up early and start your Saturday with an energizing yoga session led by Jacyln Chan, designed to awaken the body and enhance flexibility. Next, join Jacyln in embracing a moment of intentional pause and presence with the Mindful Silent Workshop, where participants are encouraged to disconnect from digital distractions. With over 15 years of experience in commercial, operational, and people leadership roles, Jacyln is the founder of Noetic Movement, a wellness and leadership company dedicated to harnessing the power of intentional pausing.

Take a mid-day break with Samuel Lim, owner of Fire City Gym, to improve your range of motion through a series of light mobility exercises with some fun. Fire City Gym is a close-knit fitness community offering a variety of classes suitable for all fitness levels, focusing on strengthening muscles to promote better movement, flexibility, and ease in both daily activities and workouts.

Engage your senses at the scent workshop by Lynk Fragrances, a Singapore-based brand committed to using only the finest all-natural ingredients sourced from the United States and Europe. Create your own personalized essential oil blend to accompany you throughout the retreat.

Immerse yourself in a deeply restorative sound bath session with Dawn Sim, an experienced yoga practitioner, teacher, and mindfulness coach. Let the soothing vibrations of gongs and singing bowls guide you into a state of profound relaxation and self-awareness, enveloping you in a cocoon of tranquility. For an even more immersive experience, bring along your handmade essential oil, enhancing the sensory journey.

Conclude the evening with a gathering over dinner, offering the perfect opportunity to connect with your retreat mates and hosts, reflecting on the transformative experiences shared throughout the retreat.

On the final day of the retreat, lace up for an invigorating 5KM scenic run around Marina Bay with our Run Concierge, Eddie Chang, as you take in the breathtaking waterfront views. After the run, accelerate your post-workout recovery and reduce muscle soreness with a cold ice bath at PURE Fitness or enjoy the rest of the day at your own pace until check-out at 2PM.

Use this time for self-reflection, indulge in a rejuvenating spa treatment, or unwind in the luxurious facilities of our award-winning Heavenly Spa by Westin on Level 35. Relax in the whirlpool, refresh under the experience shower, or immerse yourself in the calming aromatherapy steam bath—the perfect way to conclude your wellness journey.

Package includes:

For room reservation, visit thewestinsingapore.com or email Reservations.Singapore3@westin.com  

*Activities listed above might be subject to change. For most updated activities, please visit our website here.

About The Westin Singapore

As Singapore’s first integrated hotel located within an office building, The Westin Singapore occupies levels 32 to 46 of Asia Square Tower 2 commercial development in Marina Bay, the heart of Singapore’s bustling financial district. The hotel offers 305 guestrooms and suites, four distinct dining venues, an outdoor infinity pool with a stunning view over Singapore’s south coast, the Heavenly Spa by Westin™, WestinWORKOUT® fitness studio equipped with state-of-the-art Technogym and TRX fitness equipment and 1,350 square meters of versatile event spaces, all designed with guests’ well-being in mind.

For more information, please visit thewestinsingapore.com.

About Westin® Hotels & Resorts 

Westin Hotels & Resorts, hospitality’s global leader in well-being for more than a decade, empowers guests to transcend the rigors of travel while on the road through the brand’s Six Pillars of well-being: Sleep Well, Eat Well, Move Well, Feel Well, Work Well, and Play Well. At more than 240 hotels and resorts in over 40 countries and territories, guests can benefit from distinct wellness experiences including the brand’s iconic and award-winning Heavenly® Bed, signature WestinWORKOUT® offerings such as its 24/7 Fitness Studios, WestinWORKOUT Routes, and its versatile Gear Lending program featuring the latest in recovery and strength training from Hyperice and Bala, delicious and nutritious menu offerings on their Eat Well menu, and more. For more information, please visit www.westin.com and stay connected on X, Instagram, TikTok, and Facebook. Westin is proud to participate in Marriott Bonvoy®, the global travel program from Marriott International. The program offers members an extraordinary portfolio of global brands, exclusive experiences on Marriott Bonvoy Moments and unparalleled benefits including free nights and Elite status recognition. To enroll for free or for more information about the program, visit marriottbonvoy.com.

About Marriott International

Marriott International, Inc. (NASDAQ: MAR) is based in Bethesda, Maryland, USA, and encompasses a portfolio of nearly 9,100 properties across more than 30 leading brands in 142 countries and territories. Marriott operates and franchises hotels and licenses vacation ownership resorts all around the world. The company offers Marriott Bonvoy®, its highly awarded travel program.  For more information, please visit our website at www.marriott.com, and for the latest company news, visit www.marriottnewscenter.com.  In addition, connect with us on Facebook and @MarriottIntl on X and Instagram.

Akeso Announces Completion of Patient Enrollment in The Phase III Clinical Trial of Cadonilimab for Adjuvant Treatment of High-Risk Recurrent Hepatocellular Carcinoma

HONG KONG, March 6, 2025 /PRNewswire/ — Akeso, Inc. (9926. HK) (“Akeso” or the “Company”) is pleased to announce the completion of patient enrollment for its Phase III registrational clinical trial (COMPASSION-22/AK104-306) evaluating cadonilimab, the world’s first PD-1/CTLA-4 bispecific antibody independently developed by the company, as an adjuvant treatment for hepatocellular carcinoma (HCC) with high recurrence risk following curative resection or ablation.

The completion of patient enrollment in the COMPASSION-22/AK104-306 trial marks a significant milestone in the clinical development of cadonilimab for HCC. In addition to this Phase III study, another Phase III trial investigating cadonilimab in combination with lenvatinib and transarterial chemoembolization (TACE) for the treatment of unresectable intermediate to advanced HCC is currently progressing on schedule. The extensive exploration of combination therapies involving cadonilimab for HCC is expected to offer more effective treatment options for both early-stage and advanced HCC patients.

HCC is one of the most common malignant tumors globally. According to 2024 data, there are about 865,000 new cases of liver cancer worldwide, with 370,000 occurring in China. The recurrence rate after surgery is high, especially in patients with high-risk factors, with a five-year recurrence rate exceeding 70%. Currently, no standard adjuvant treatment exists for HCC in clinical practice. Identifying effective adjuvant therapies to reduce recurrence risk and extend survival is a critical unmet need in HCC treatment.

Cadonilimab is the world’s first approved bispecific immunotherapy for cancer. Previous studies have shown its significant efficacy and favorable safety profile in treating HCC. Research presented at the 2023 European Society for Medical Oncology (ESMO) Asia Annual Meeting demonstrated that cadonilimab combined with FOLFOX-HAIC as neoadjuvant therapy for resectable multinodular HCC achieved a 100% disease control rate (DCR) with manageable safety. Furthermore, data from the 2023 ESMO Congress highlighted that cadonilimab combined with lenvatinib as a first-line treatment for advanced HCC showed superior antitumor activity compared to approved therapies, effectively controlling tumor progression and offering long-term survival benefits over current treatment options.

Akeso will continue to advance cadonilimab clinical development for multiple malignant tumors, with the aim to provide more therapeutic options for patients worldwide. Currently, cadonilimab is currently involved in over 23 clinical studies across 16 indications, including gastric cancer, lung cancer, liver cancer, cervical cancer, and pancreatic cancer. It has already received approval for the treatment of recurrent/metastatic cervical cancer and first-line gastric cancer. The sNDA for cadonilimab for the treatment of first-line cervical cancer is currently under review. Additionally, five Phase III trials for HCC, non-small cell lung cancer (NSCLC), and gastric cancer are underway. Studies across multiple indications, including cervical cancer, gastric cancer, and NSCLC, have shown that cadonilimab offers meaningful efficacy benefits in all patient populations, regardless of PD-L1 expression levels (high, low, or negative). These patient data indicates that cadonilimab can also significantly broadens the eligible patient population that can benefit from cancer immunotherapies.

About Akeso
Akeso (HKEX: 9926.HK) is a leading biopharmaceutical company committed to the research, development, manufacturing and commercialization of the world’s first or best-in-class innovative biological medicines. Founded in 2012, the company has created a unique integrated R&D innovation system with the comprehensive end-to-end drug development platform (ACE Platform) and bi-specific antibody drug development technology (Tetrabody) as the core, a GMP-compliant manufacturing system and a commercialization system with an advanced operation mode, and has gradually developed into a globally competitive biopharmaceutical company focused on innovative solutions. With fully integrated multi-functional platform, Akeso is internally working on a robust pipeline of over 50 innovative assets in the fields of cancer, autoimmune disease, inflammation, metabolic disease and other major diseases. Among them, 23 candidates have entered clinical trials (including 11 bispecific/multispecific antibodies and bispecific antibody-drug conjugates). Additionally, 5 new drugs are commercially available, and 5 new drugs across 7 indications are currently under regulatory review for approval. Through efficient and breakthrough R&D innovation, Akeso always integrates superior global resources, develops the first-in-class and best-in-class new drugs, provides affordable therapeutic antibodies for patients worldwide, and continuously creates more commercial and social values to become a global leading biopharmaceutical enterprise.

For more information, please visit https://www.akesobio.com/en/about-us/corporate-profile/ and follow us on Linkedin.

CStone Submits Clinical Trial Application in Australia for CS5001 (ROR1 ADC) in Combination with First-Line Standard-of-Care for DLBCL

  • Phase Ib trial to evaluate CS5001 in combination with R-CHOP as a first-line treatment for diffuse large B-cell lymphoma (DLBCL), aiming to reshape the standard-of-care landscape.
  • CS5001 is also being investigated globally in a multi-center Phase Ib clinical trial for multiple solid tumor types.

SUZHOU, China, March 6, 2025 /PRNewswire/ — CStone Pharmaceuticals (“CStone”, HKEX: 2616), a biopharmaceutical company dedicated to developing innovative cancer therapies, today announced the submission of a Phase Ib clinical trial application in Australia for CS5001, its ROR1-targeting antibody-drug conjugate (ADC), in combination with first-line standard-of-care (SoC) for DLBCL. CS5001 is also being evaluated as both a monotherapy and in combination with a PD-L1 inhibitor for advanced solid tumors in an ongoing global multi-center clinical trial.

Building on promising data from CS5001 monotherapy in later-line aggressive and indolent lymphomas, this Phase Ib trial aims to expand the therapeutic potential of CS5001 across all DLBCL stages and solid tumors. The study will explore:

  • CS5001 + R-CHOP: First-line treatment for DLBCL patients who have not received prior systemic therapy.
  • CS5001 + SoC: For patients with relapsed or refractory DLBCL.
  • CS5001 Monotherapy: Targeting ROR1-expressing solid tumors.
  • CS5001 + Sugemalimab: Combination therapy for advanced solid tumors.

Dr. Jason Yang, CEO, President of R&D, and Executive Director at CStone, stated: “We are thrilled to reach another key clinical milestone for CS5001. The existing data underscore its broad potential in both lymphomas and solid tumors. Notably, a ROR1 ADC combined with R-CHP has demonstrated an impressive complete response (CR) rate in a Phase II trial for first-line DLBCL. As we advance from late-line monotherapy to frontline combination therapy, we are optimistic that CS5001 will provide significant clinical benefits to DLBCL patients and establish itself as a first-line treatment option. Meanwhile, we continue to explore CS5001’s potential in solid tumors and eagerly anticipate further positive outcomes.”

The global multi-center Phase Ib trial for CS5001 is actively enrolling patients across the United States, Australia, and China. Recruitment is ongoing for monotherapy cohorts targeting aggressive and indolent advanced lymphomas, which could potentially expand into a Phase II single-arm registrational study. Additional cohorts, including the first-line DLBCL combination therapy and solid tumor monotherapy and combination therapy arms, will be initiated soon.

About CS5001 (ROR1 ADC)

CS5001 is a clinical-stage antibody-drug conjugate (“ADC”) targeting ROR1 (receptor tyrosine kinase-like orphan receptor 1). CS5001 has been uniquely designed with proprietary tumor-cleavable linker and pyrrolobenzodiazepine (“PBD”) prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps address the toxicity associated with traditional PBD payloads, leading to a better safety profile. CS5001 has demonstrated complete tumor suppression in several preclinical cancer models and demonstrated favorable serum half-life and pharmacokinetic characteristics. CS5001 is a promising candidate drug with precision treatment potential in both hematologic tumors and malignant solid tumors. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio of which enables homogeneous production and large-scale manufacturing.

In October 2020, CStone signed a licensing agreement with LigaChem Biosciences, Inc. (LCB) for the development and commercialization of CS5001 which was originally generated by collaboration of LCB and ABL Bio, both South Korea-based leading biotech companies. Under the agreement, CStone obtains the exclusive global right to develop and commercialize CS5001 outside the Republic of Korea.

The first-in-human data for CS5001 in patients with advanced solid tumors and lymphomas was presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting. Additionally, the latest clinical data on CS5001 as a monotherapy in patients with advanced lymphomas has recently been presented at the 66th American Society of Hematology (ASH) Annual Meeting.

CS5001 has demonstrated encouraging safety and robust anti-tumor activity in the Phase 1a dose escalation trials across 10 dose levels.

  • At the tentative recommended Phase 2 dose (RP2D) of DL8 (125 μg/kg), CS5001 achieved objective response rates (ORRs) of 70% in advanced B-cell lymphoma and 100% in Hodgkin lymphoma.
  • Encouraging efficacy signals were also observed in advanced solid tumors, including non-small cell lung cancer and pancreatic cancer.
  • CS5001 was well tolerated in heavily pre-treated patients with advanced B-cell lymphomas and solid tumors.

About CStone

CStone (HKEX: 2616), established in late 2015, is an innovation-driven biopharmaceutical company focused on the research and development of anti-cancer therapies. Dedicated to addressing patients’ unmet medical needs in China and globally, the Company has made significant strides since its inception. To date, the Company has successfully launched 4 innovative drugs and secured approvals for 16 new drug applications (NDAs) covering 9 indications. The company’s pipeline is balanced by 16 promising candidates, featuring potentially first-in-class or best-in-class antibody-drug conjugates (ADCs), multispecific antibodies, immunotherapies and precision medicines. CStone also prides itself on a management team with comprehensive experiences and capabilities that span the entire drug development spectrum, from preclinical and translational research to clinical development, drug manufacturing, business development, and commercialization. For more information about CStone, please visit www.cstonepharma.com.

Forward-looking statements

The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.

Disclaimer: only for communication and scientific use by medical and health professionals, it is not intended for promotional purposes.

FARMLORE IN BENGALURU IS UNVEILED AS THE WINNER OF THE AMERICAN EXPRESS ONE TO WATCH AWARD 2025 AS PART OF ASIA’S 50 BEST RESTAURANTS

LONDON, March 6, 2025 /PRNewswire/ — Farmlore in Bengaluru has been honoured as the 2025 recipient of the prestigious American Express One To Watch Award. Selected by the 50 Best team based on the votes of its Academy and specific editorial criteria, this award highlights dining establishments that showcase exceptional culinary talent, creativity and the potential to secure a spot in the Asia’s 50 Best Restaurants list over the coming years.

Asia's 50 Best Restaurants announces Bengaluru-based restaurant Farmlore as the recipient of the American Express One To Watch Award 2025
Asia’s 50 Best Restaurants announces Bengaluru-based restaurant Farmlore as the recipient of the American Express One To Watch Award 2025

Farmlore, an 18-seater dining experience on a 37-acre farm near Bengaluru, India, is the brainchild of chef Johnson Ebenezer and entrepreneur Kaushik Raju. The restaurant embodies a farm-to-table ethos, driven by seasonality, sustainability and local produce. Its name cleverly combines ‘folklore’ and ‘locavore,’ reflecting its dedication to celebrating regional ingredients and cultural narratives.

William Drew, Director of Content for Asia’s 50 Best Restaurants, says: “Amid the restaurants with a ‘farm-to-table’ philosophy, Farmlore stands apart with its immersive experience, nestled within an actual working farm. We congratulate chef Johnson and the teams behind the kitchens and farms at Farmlore, on this very well-earned accolade.”

The restaurant’s menus, shaped by the freshest harvests from its farm, consistently highlight core themes, including a strong South Indian influence. Here they prioritise ethical, organic farming principles passed down through generations that also preserve soil health while creating nutrient-rich produce. The design harmonises with its natural surroundings, featuring earthy tones, open spaces and a minimalist aesthetic that fosters an intimate yet direct connection to nature.

On winning, Chef Johnson says, “We are truly humbled to be recognised by Asia’s 50 Best Restaurants. This award is a testament to our unwavering commitment to doing things the right way while staying true to our values and prioritising ethics over expediency. It’s also a testament to the younger generation of chefs who dare to stick to their strengths and roots.”

Farmlore will be further celebrated at the in-person awards ceremony held on 25 March 2025 in Seoul in collaboration with host destination partner, the Ministry of Agriculture, Food and Rural Affairs and the Seoul Metropolitan Government. The awards ceremony will be streamed live via the link here. The announcement of the list and individual awards can be followed via the 50 Best social media channels, with the livestream beginning at 20:00 Korea time.

Media Centre:
https://mediacentre.theworlds50best.com/

SK keyfoundry Launches 3D Hall-effect Sensor Technology Capable of Measuring Speed and Direction

SEOUL, South Korea, March 6, 2025 /PRNewswire/ — SK keyfoundry, an 8-inch pure-play foundry in Korea, announced today that it offers a new 3D Hall-effect sensor technology that can measure speed and direction through three-dimensional magnetic field detection for its foundry customers.

The Hall-effect sensor is a device that measures the strength of a magnetic field using the Hall-effect, which detects the voltage difference generated when a conductor or semiconductor passes through a magnetic field. The measured magnetic field is utilized in applications that leverage the position, speed, rotation, direction, and current of devices.

SK keyfoundry has provided a variety of products using existing 1D (one-dimensional) and 2D (two-dimensional) Hall-effect sensors, and this new 3D Hall-effect sensor integrates both Vertical and Planar Hall-effect sensors on a single chip. It features enhanced sensitivity beyond that of existing 2D products, enabling real-time measurement of minute three-dimensional direction and speed changes with rapid response times.

Another important feature of the 3D Hall-effect sensor provided by SK keyfounrdry is that it can be designed to easily integrate into customer products by adding masks to existing processes. Additionally, the integration of the 3D Hall-effect sensor is offered across multiple nodes in the range of 0.13μm to 0.18μm while maintaining electrical characteristics.

The new 3D Hall-effect sensor is expected to be utilized in various fields. In particular, it can be applied in the automotive sector for safe driving assistance and autonomous driving systems, in consumer electronics for smart appliances and gaming consoles, and in industrial automation for robot control, drones, virtual reality, augmented reality, and wearable devices.

Derek D. Lee, the CEO of SK keyfoundry, stated, “The newly launched 3D Hall-effect sensor technology is expected to be utilized in the design of products across various industries, including home appliances, automotive, robotics, and drones, due to its high sensitivity and ability to detect minute three-dimensional movements.” He added, “We plan to support our customers in integrating more diverse functions into a single semiconductor through ongoing technology openness.”

About SK keyfoundry

Headquartered in Korea, SK keyfoundry provides specialty Analog and Mixed-Signal foundry services for semiconductor companies to serve a wide range of applications in the consumer, communications, computing, automotive and industrial industries. With a broad range of technology portfolios and process nodes, SK keyfoundry has the flexibility and capability to meet the ever-evolving needs of semiconductor companies across the globe. Please visit https://www.skkeyfoundry.com for more information.

Apollo Group TV Expands Payment Options Making Premium Streaming More Accessible with Raydium Solutions

BOSTON, March 6, 2025 /PRNewswire/ — In a strategic partnership with Raydium Solutions, Apollo Group TV is making premium streaming more accessible by introducing credit card payments for the first time. Previously limited to Bitcoin transactions, this major shift allows more users to enjoy secure, high-quality streaming with greater flexibility. As a leading provider of IPTV services, Apollo Group TV continues to redefine home entertainment with a vast selection of content, cutting-edge streaming technology, and customer-focused innovations.


Unmatched Variety of Live TV and On-Demand Content

Apollo Group TV offers an impressive catalog of 24,000+ live channels and 95,000+ Video-on-Demand (VOD) titles, spanning movies, TV series, news, sports, and international programming. With access to premium channels across multiple genres, subscribers can enjoy the best in live television, blockbuster films, and exclusive series all in one place.

Designed to meet the needs of a diverse audience, Apollo Group TV ensures that viewers always have access to the latest Hollywood hits, classic films, trending TV shows, and live sports events without limitations.

Expanding Payment Options: Now Accepting Credit Cards

Through its collaboration with Raydium Solutions, Apollo Group TV has expanded its payment options, now accepting credit cards alongside cryptocurrency payments. This move reflects Apollo TV’s commitment to making its premium IPTV service more accessible to a wider audience.

“With consumer demand for seamless and secure transactions rising, expanding payment methods was a natural step,” said a spokesperson from Raydium Solutions, the technology partner supporting this transition. “This collaboration ensures that more users can access Apollo TV’s premium streaming service with ease.”

High-Definition Streaming with Advanced Technology

Apollo Group TV delivers an unparalleled viewing experience, offering crystal-clear HD and 4K resolution for a cinematic feel at home. The platform utilizes anti-freeze technology to eliminate buffering, ensuring smooth and uninterrupted playback.

With a 99.9% uptime guarantee, Apollo TV users can rely on a stable, high-performance streaming service at any time—whether watching live TV, sports, or on-demand content.

Seamless User Experience & Smart Device Compatibility

Apollo Group TV enhances navigation with an Electronic Program Guide (EPG) TV Guide, making it easy to browse and manage content. The intuitive interface allows users to switch between channels effortlessly and discover new content.

The platform is compatible with a wide range of devices, including smart TVs, streaming boxes, mobile devices, and tablets, ensuring maximum flexibility for subscribers.

Reliable Customer Support and Lifetime Assistance

Apollo Group TV is dedicated to customer satisfaction, offering 24/7 live chat support to assist with technical issues, account management, and content recommendations.

Through its strategic technology partnership with Raydium Solutions, Apollo TV ensures that its platform remains highly secure, accessible, and future-ready, continuously improving the user experience.

Join the Future of Streaming with Apollo Group TV

With its expansive content library, advanced streaming technology, and newly expanded payment options, Apollo Group TV is setting new standards in digital entertainment.

For more details on subscription plans and the latest updates, visit ApolloTVsGroup.com.

About Apollo Group TV

Apollo Group TV is a leading IPTV streaming service, providing access to thousands of live TV channels, movies, and series in high-definition quality. With a commitment to innovation, top-tier customer support, and a seamless viewing experience, Apollo Group TV continues to revolutionize premium home entertainment.

Baidu Announces Pricing of CNY10 Billion CNY-denominated Senior Notes

BEIJING, March 6, 2025 /PRNewswire/ — Baidu, Inc. (NASDAQ: BIDU and HKEX: 9888 (HKD Counter) and 89888 (RMB Counter)), (“Baidu” or the “Company”), a leading AI company with strong Internet foundation, today announced the pricing of its offering of CNY10 billion aggregate principal amount of CNY-denominated senior unsecured notes (the “Notes”). The Notes were offered in offshore transactions outside the United States to certain non-U.S. persons (the “Notes Offering”) in reliance on Regulation S under the United States Securities Act of 1933, as amended (the “Securities Act”). 

The Notes Offering consists of CNY7.5 billion of 2.70% notes due 2030 and CNY2.5 billion of 3.00% notes due 2035. The Company expects to close the Notes Offering on or about March 12, 2025, subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the Notes Offering for general corporate purposes, including repayment of certain existing indebtedness, payment of interest and general corporate purposes.

The Notes have not been and will not be registered under the Securities Act or any state securities laws. They may not be offered or sold in the United States or to, or for the account or benefits of, U.S. persons (as defined in Regulation S under the Securities Act) except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act.

The Notes are expected to be listed on The Stock Exchange of Hong Kong Limited (the “Hong Kong Stock Exchange”).

This announcement shall not constitute an offer to sell or a solicitation of an offer to purchase any securities, in the United States or elsewhere, and shall not constitute an offer, solicitation or sale of the securities in any state or jurisdiction in which such an offer, solicitation or sale would be unlawful. Any offering of securities will be made by means of one or more offering documents, which will contain detailed material information about the Company and its operational and financial performance.

This announcement contains information about the pending Notes Offering, and there can be no assurance that the Notes Offering will be completed.

About Baidu

Founded in 2000, Baidu’s mission is to make the complicated world simpler through technology. Baidu is a leading AI company with strong Internet foundation, trading on Nasdaq under “BIDU” and HKEX under “9888”. One Baidu ADS represents eight Class A ordinary shares.

Safe Harbor Statement

This announcement contains forward-looking statements. These statements are made under the “safe harbor” provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as “will,” “expects,” “anticipates,” “future,” “intends,” “plans,” “believes,” “estimates,” “confident” and similar statements. Baidu may also make written or oral forward-looking statements in its periodic reports to the SEC, in announcements made on the website of the Hong Kong Stock Exchange, in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including but not limited to statements about Baidu’s beliefs and expectations, are forward-looking statements. Forward-looking statements involve inherent risks and uncertainties. A number of factors could cause actual results to differ materially from those contained in any forward-looking statement, including but not limited to the following: Baidu’s growth strategies; its future business development, including development of new products and services; its ability to attract and retain users and customers; competition in the Chinese Internet search and newsfeed market; competition for online marketing customers; changes in the Company’s revenues and certain cost or expense items as a percentage of its revenues; the outcome of ongoing, or any future, litigation or arbitration, including those relating to intellectual property rights; the expected growth of the Chinese-language Internet search and newsfeed market and the number of Internet and broadband users in China; Chinese governmental policies relating to the Internet and Internet search providers, and general economic conditions in China and elsewhere. Further information regarding these and other risks is included in the Company’s annual report on Form 20-F and other documents filed with the SEC, and announcements on the website of the Hong Kong Stock Exchange. Baidu does not undertake any obligation to update any forward-looking statement, except as required under applicable law. All information provided in this announcement is as of the date of the announcement, and Baidu undertakes no duty to update such information, except as required under applicable law.